Advances of Hydroxyapatite Hybrid Organic Composite Used as Drug or Protein Carriers for Biomedical Applications: A Review

✅ 全文

羟基磷灰石杂化有机复合材料作为药物或蛋白质载体在生物医学应用中的进展:综述

作者 Ssu-Meng Huang; Shih-Ming Liu; Chia‐Ling Ko; Wen‐Cheng Chen 期刊 Polymers 发表日期 2022 ISSN 2073-4360 DOI 10.3390/polym14050976 类型 原创研究 (Original Research)

📄 英文摘要 English Abstract

EN

Hydroxyapatite (HA), especially in the form of HA nanoparticles (HANPs), has excellent bioactivity, biodegradability, and osteoconductivity and therefore has been widely used as a template or additives for drug delivery in clinical applications, such as dentistry and orthopedic repair. Due to the atomically anisotropic distribution on the preferred growth of HA crystals, especially the nanoscale rod-/whisker-like morphology, HA can generally be a good candidate for carrying a variety of substances. HA is biocompatible and suitable for medical applications, but most drugs carried by HANPs have an initial burst release. In the adsorption mechanism of HA as a carrier, specific surface area, pore size, and porosity are important factors that mainly affect the adsorption and release amounts. At present, many studies have developed HA as a drug carrier with targeted effect, porous structure, and high porosity. This review mainly discusses the influence of HA structures as a carrier on the adsorption and release of active molecules. It then focuses on the benefits and effects of different types of polymer-HA composites to re-examine the proteins/drugs carry and release behavior and related potential clinical applications. This literature survey can be divided into three main parts: 1. interaction and adsorption mechanism of HA and drugs; 2. advantages and application fields of HA/organic composites; 3. loading and drug release behavior of multifunctional HA composites in different environments. This work also presents the latest development and future prospects of HA as a drug carrier.

📄 中文摘要 Chinese Abstract

中文
羟基磷灰石(HA),尤其是纳米羟基磷灰石(HANPs)形式,具有优异的生物活性、生物降解性和骨传导性,因此被广泛用作临床应用中药物递送的模板或添加剂,如牙科和骨科修复。由于HA晶体在优先生长方向上原子分布的各向异性,特别是纳米级棒状/晶须状形态,HA通常可以成为携带多种物质的良好候选材料。HA具有生物相容性,适用于医学应用,但大多数由HANPs携带的药物存在初始突释现象。在HA作为载体的吸附机制中,比表面积、孔径和孔隙率是主要影响吸附量和释放量的重要因素。目前,许多研究已开发出具有靶向效应、多孔结构和高孔隙率的HA药物载体。 HA具有六方晶体结构,分子式为Ca10(PO4)6(OH)2,HANPs的结构具有两个不同的结合位点。例如,HANPs两端带有带负电的磷酸根阴离子,侧面带有带正电的Ca2+阳离子。HA是人体骨骼的必需矿物质,骨骼由70%的低结晶或无定形磷灰石、30%的胶原蛋白和骨髓细胞组成。目前,磷灰石的制备方法主要包括湿法、干法、溶胶-凝胶法、生物组织合成法、水热法和冷冻干燥法。HA具有良好的生物活性、生物相容性和无毒性。它广泛用于硬组织(如骨骼和牙齿)的填充和修复。

📋 英文结构化总结 English Structured Summary

全文整理

EN

Background:

Hydroxyapatite (HA), especially in the form of HA nanoparticles (HANPs), has excellent bioactivity, biodegradability, and osteoconductivity and therefore has been widely used as a template or additives for drug delivery in clinical applications, such as dentistry and orthopedic repair. Due to the atomically anisotropic distribution on the preferred growth of HA crystals, especially the nanoscale rod-/whisker-like morphology, HA can generally be a good candidate for carrying a variety of substances. HA is biocompatible and suitable for medical applications, but most drugs carried by HANPs have an initial burst release. In the adsorption mechanism of HA as a carrier, specific surface area, pore size, and porosity are important factors that mainly affect the adsorption and release amounts. At present, many studies have developed HA as a drug carrier with targeted effect, porous structure, and high porosity.

HA has a hexagonal crystal structure with the molecular formula Ca10(PO4)6(OH)2, and the structure of HANPs has two distinct binding sites. For example, HANPs have negatively charged phosphate anions at both ends and positively charged Ca2+ cations on the sides. HA is an essential mineral for human bones, which consist of 70% low-crystalline or amorphous apatite, 30% collagen, and bone marrow cells. At present, apatite preparation methods mainly include wet, dry, sol–gel, biological tissue synthesis, hydrothermal, and freeze-drying methods. HA has good biological activity, biocompatibility, and non-toxicity. It is widely used in the filling and repair of hard tissues, such as bones and teeth.

Methods:

This literature survey can be divided into three main parts: 1. interaction and adsorption mechanism of HA and drugs; 2. advantages and application fields of HA/organic composites; 3. loading and drug release behavior of multifunctional HA composites in different environments. This work also presents the latest development and future prospects of HA as a drug carrier.

Results:

When HA is mainly used as a carrier, especially in the form of HANPs, it can carry proteins, growth factors, antibiotics, anti-inflammatory drugs, tumor drugs, etc., which can shorten the treatment time, achieve local sustained release, and guide tissue regeneration. The adsorption capacity of HANPs directly depends on their surface area, morphology, and hydration, which are usually regulated by pH and electrolyte concentration. For drug delivery applications, the porosity and pore distribution in HANPs are important to determine drug loading capacity, drug delivery efficiency, and release kinetics. Since charged and polar groups impart important properties to proteins through the formation of ion pairs, hydrogen bonds, and other less specific electrostatic interactions, the surface charge of HANPs can control protein binding through hydrogen bonding or electrostatic interactions, thereby providing binding sites between the protein molecules and the surface of HANPs. Therefore, calcium cations (Ca2+) and phosphate anions (PO43−) in HANPs can be used as preferential binding sites for proteins; the protein–mineral ion complex can be formed as a protein with specific ligand interactions; for example, peptides are inherently capable of binding Ca2+ to carbonyls by chelation.

The composite of HANPs and natural and synthetic polymers effectively solves the HANP problems, such as high brittleness, uncontrollable degradation rate, poor plasticity, and easy agglomeration. Methods for compositing HANPs into a polymer matrix for processing include electrospinning, three-dimensional (3D) printing, freeze drying, etc. These hybrid composites can be formed into desired morphologies of braided thread, thin film, nanofiber composed membranes, scaffolds, microspheres or nano-beads, and sprayed coatings to enhance mechanical properties and adapt to target applications.

Data Summary:

Human bones consist of 70% low-crystalline or amorphous apatite, 30% collagen, and bone marrow cells. HANPs have a rod-like shape, which prefers particle growth along the c-axis with a strong inhomogeneous electron distribution and a high surface area. The morphology of HANPs has a significant effect on regulating ion release and further controls the HANP interaction with protein (Pepsin A).

Conclusions:

Based on the review, HA is widely used in orthopedics and drug delivery systems due to its excellent biocompatibility, osteoconductivity, osteoinductivity, and osteogenic ability. The composite of HANPs and natural and synthetic polymers effectively solves the HANP problems, such as high brittleness, uncontrollable degradation rate, poor plasticity, and easy agglomeration, and these hybrid composites are widely used in various medicines, not limited to the regeneration of bone tissues.

Practical Significance:

These hybrid composites can be formed into desired morphologies such as braided thread, thin film, nanofiber composed membranes, scaffolds, microspheres or nano-beads, and sprayed coatings to enhance mechanical properties and adapt to target applications. In addition to binding HANPs, these composites can be loaded with drugs, magnetic quantum dots, or grafted with growth factors or proteins according to different clinical needs, enabling real-world applications in orthopedics, dentistry, and various drug delivery systems.

📋 中文结构化总结 Chinese Structured Summary

中文

背景:

羟基磷灰石(HA),尤其是纳米羟基磷灰石(HANPs)形式,具有优异的生物活性、生物降解性和骨传导性,因此被广泛用作临床应用中药物递送的模板或添加剂,如牙科和骨科修复。由于HA晶体在优先生长方向上原子分布的各向异性,特别是纳米级棒状/晶须状形态,HA通常可以成为携带多种物质的良好候选材料。HA具有生物相容性,适用于医学应用,但大多数由HANPs携带的药物存在初始突释现象。在HA作为载体的吸附机制中,比表面积、孔径和孔隙率是主要影响吸附量和释放量的重要因素。目前,许多研究已开发出具有靶向效应、多孔结构和高孔隙率的HA药物载体。

HA具有六方晶体结构,分子式为Ca10(PO4)6(OH)2,HANPs的结构具有两个不同的结合位点。例如,HANPs两端带有带负电的磷酸根阴离子,侧面带有带正电的Ca2+阳离子。HA是人体骨骼的必需矿物质,骨骼由70%的低结晶或无定形磷灰石、30%的胶原蛋白和骨髓细胞组成。目前,磷灰石的制备方法主要包括湿法、干法、溶胶-凝胶法、生物组织合成法、水热法和冷冻干燥法。HA具有良好的生物活性、生物相容性和无毒性。它广泛用于硬组织(如骨骼和牙齿)的填充和修复。

方法:

本文献综述可分为三个主要部分:1. HA与药物的相互作用和吸附机制;2. HA/有机复合材料的优势和应用领域;3. 多功能HA复合材料在不同环境中的负载和药物释放行为。本工作还介绍了HA作为药物载体的最新发展和未来前景。

结果:

当HA主要作为载体使用时,特别是以HANPs形式,它可以携带蛋白质、生长因子、抗生素、抗炎药物、肿瘤药物等,从而缩短治疗时间,实现局部缓释,并引导组织再生。HANPs的吸附能力直接取决于其表面积、形态和水合作用,这些通常由pH值和电解质浓度调节。对于药物递送应用,HANPs中的孔隙率和孔隙分布对于确定药物负载能力、药物递送效率和释放动力学至关重要。由于带电和极性基团通过形成离子对、氢键和其他不太特异性的静电相互作用赋予蛋白质重要性质,HANPs的表面电荷可以通过氢键或静电相互作用控制蛋白质结合,从而提供蛋白质分子与HANPs表面之间的结合位点。因此,HANPs中的钙阳离子(Ca2+)和磷酸根阴离子(PO43-)可用作蛋白质的优先结合位点;蛋白质-矿物质离子复合物可以形成具有特定配体相互作用的蛋白质;例如,肽本质上能够通过螯合作用将Ca2+结合到羰基上。

HANPs与天然和合成聚合物的复合材料有效解决了HANPs的问题,如高脆性、不可控的降解速率、较差的塑性和易团聚。将HANPs复合到聚合物基质中进行加工的方法包括静电纺丝、三维(3D)打印、冷冻干燥等。这些杂化复合材料可以形成所需的形态,如编织线、薄膜、纳米纤维组成的膜、支架、微球或纳米珠以及喷涂涂层,以增强机械性能并适应目标应用。

数据总结:

人体骨骼由70%的低结晶或无定形磷灰石、30%的胶原蛋白和骨髓细胞组成。HANPs具有棒状形态,倾向于沿c轴优先生长,具有强烈的不均匀电子分布和高表面积。HANPs的形态对调节离子释放具有显著影响,并进一步控制HANPs与蛋白质(胃蛋白酶A)的相互作用。

结论:

基于综述,HA因其优异的生物相容性、骨传导性、骨诱导性和成骨能力,被广泛应用于骨科和药物递送系统。HANPs与天然和合成聚合物的复合材料有效解决了HANPs的问题,如高脆性、不可控的降解速率、较差的塑性和易团聚,这些杂化复合材料广泛用于各种药物,不仅限于骨组织的再生。

实际意义:

这些杂化复合材料可以形成所需的形态,如编织线、薄膜、纳米纤维组成的膜、支架、微球或纳米珠以及喷涂涂层,以增强机械性能并适应目标应用。除了结合HANPs外,这些复合材料还可以根据不同临床需求负载药物、磁性量子点,或接枝生长因子或蛋白质,实现在骨科、牙科和各种药物递送系统中的实际应用。

📖 英文全文 English Full Text

EN

Review

Advances of Hydroxyapatite Hybrid Organic Composite Used as Drug or Protein Carriers for Biomedical Applications: A Review Ssu-Meng Huang 1,†, Shih-Ming Liu 1,†, Chia-Ling Ko 1 and Wen-Cheng Chen 1,2,3,* Advanced Medical Devices and Composites Laboratory, Department of Fiber and Composite Materials, Feng Chia University, Taichung 407, Taiwan; dream161619192020@gmail.com (S.-M.H.); 0203home@gmail.com (S.-M.L.); rayko1024.rb@gmail.com (C.-L.K.) 2 Department of Fragrance and Cosmetic Science, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan 3 Dental Medical Devices and Materials Research Center, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan * Correspondence: wencchen@mail.fcu.edu.tw † These authors contributed equally to this work. 1

Citation: Huang, S.-M.; Liu, S.-M.; Ko, C.-L.; Chen, W.-C. Advances of Hydroxyapatite Hybrid Organic Composite Used as Drug or Protein Carriers for Biomedical Applications: A Review. Polymers 2022, 14, 976. https://doi.org/ 10.3390/polym14050976 Academic Editor: Agnieszka Tercjak Received: 28 January 2022 Accepted: 24 February 2022 Published: 28 February 2022 Publisher’s Note: MDPI stays neu-

Abstract: Hydroxyapatite (HA), especially in the form of HA nanoparticles (HANPs), has excellent bioactivity, biodegradability, and osteoconductivity and therefore has been widely used as a template or additives for drug delivery in clinical applications, such as dentistry and orthopedic repair. Due to the atomically anisotropic distribution on the preferred growth of HA crystals, especially the nanoscale rod-/whisker-like morphology, HA can generally be a good candidate for carrying a variety of substances. HA is biocompatible and suitable for medical applications, but most drugs carried by HANPs have an initial burst release. In the adsorption mechanism of HA as a carrier, specific surface area, pore size, and porosity are important factors that mainly affect the adsorption and release amounts. At present, many studies have developed HA as a drug carrier with targeted effect, porous structure, and high porosity. This review mainly discusses the influence of HA structures as a carrier on the adsorption and release of active molecules. It then focuses on the benefits and effects of different types of polymer-HA composites to re-examine the proteins/drugs carry and release behavior and related potential clinical applications. This literature survey can be divided into three main parts: 1. interaction and adsorption mechanism of HA and drugs; 2. advantages and application fields of HA/organic composites; 3. loading and drug release behavior of multifunctional HA composites in different environments. This work also presents the latest development and future prospects of HA as a drug carrier.

tral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Keywords: hydroxyapatite; nanoparticles; composites; drug release; protein; template; carriers; tissue engineering; scaffold

1. Introduction Bioceramics are biocompatible ceramics, glass materials, or ceramic/glass composites designed to repair or rebuild damaged parts of human hard tissues [1]. For many decades of research, the focus has been on the mechanical properties and biocompatibility of bioceramics [2], while the current trend is toward functional polymer–bioceramic composites with additional therapeutic functions, such as antibacterial and antitumor [3]. Hydroxyapatite (HA) has a hexagonal crystal structure with the molecular formula Ca10(PO4)6(OH)2, and the structure of HA nanoparticles (HANPs) has two distinct binding sites. For example, HANPs have negatively charged phosphate anions at both ends and positively charged Ca2+ cations on the sides [4–7]. HA is an essential mineral for human

Polymers 2022, 14, 976. https://doi.org/10.3390/polym14050976 www.mdpi.com/journal/polymers Polymers 2022, 14, 976 2 of 19

bones, which consist of 70% low-crystalline or amorphous apatite, 30% collagen, and bone marrow cells [8–12]. At present, apatite preparation methods mainly include wet [13–15], dry [16–18], sol–gel [19–21], biological tissue synthesis [22–24], hydrothermal [25–27], and freeze-drying methods [28–30]. HA has good biological activity, biocompatibility, and non-toxicity. It is widely used in the filling and repair of hard tissues, such as bones and teeth [31–33]. When HA is mainly used as a carrier, especially in the form of HANPs, it can carry proteins, growth factors, antibiotics, anti-inflammatory drugs, tumor drugs, etc. [34–37], which can shorten the treatment time, achieve local sustained release, and guide tissue regeneration. The adsorption capacity of HANPs directly depends on their surface area, morphology, and hydration, which are usually regulated by pH and electrolyte concentration [38]. For drug delivery applications, the porosity and pore distribution in HANPs are important to determine drug loading capacity, drug delivery efficiency, and release kinetics [39]. Since charged and polar groups impart important properties to proteins through the formation of ion pairs, hydrogen bonds, and other less specific electrostatic interactions, the surface charge of HANPs can control protein binding through hydrogen bonding or electrostatic interactions, thereby providing binding sites between the protein molecules and the surface of HANPs [40]. Therefore, calcium cations (Ca2+) and phosphate anions (PO43−) in HANPs can be used as preferential binding sites for proteins [41,42], the protein–mineral ion complex can be formed as a protein with specific ligand interactions; for example, peptides are inherently capable of binding Ca2+ to carbonyls by chelation. HANPs are a calcium phosphate compound with similar composition to natural bone tissues and have excellent biocompatibility, osteoconductivity, osteoinductivity, and osteogenic ability; as such, HANPs are widely used in orthopedics and drug delivery systems [36,43–45]. The composite of HANPs and natural and synthetic polymers effectively solves the HANP problems, such as high brittleness, uncontrollable degradation rate, poor plasticity, and easy agglomeration [46]. Methods for compositing HANPs into a polymer matrix for processing include electrospinning, three-dimensional (3D) printing, freeze drying, etc. These hybrid composites can be formed into desired morphologies of braided thread, thin film, nanofiber composed membranes, scaffolds, microspheres or nano-beads, and sprayed coatings to enhance mechanical properties and adapt to target applications [47,48]. In addition to binding HANPs, these composites can be loaded with drugs, magnetic quantum dots, or grafted with growth factors or proteins according to different clinical needs. Depending on the resulting HANP composite polymers, these hybrid composites are widely used in various medicines, not limited to the regeneration of bone tissues. 2. HA as a Template for Protein/Drug Carriers 2.1. Carrier of HANPs for Protein Adsorption For in vivo applications, nanoparticles (NPs) are exposed to an array of biomolecules that form a corona around the NPs, which significantly alters the surface properties of the NPs. HANPs have a rod-like shape, which prefers particle growth along the c-axis with a strong inhomogeneous electron distribution and a high surface area. The morphology of HANPs has a significant effect on regulating ion release and further controls the HANP interaction with protein (Pepsin A). For example, Kadu (2021) et al. revealed the effect of four different HANP morphologies and subsequent surface modification with cetylpyridinium chloride (CPC) on protein adsorption, having Cl‒ as counter-ion [49]. The results show that the morphology of nanoparticles has a significant effect on the release of counter-ion, resulting in changes in the structural conformation of proteins that control their interactions with proteins. In addition, as the binding efficiency of modified HANPs to effective binding sites, the misfolding order of Pepsin A is short rod < long rod < spherical < cubic NPs, in which isotropic CPC has higher interaction with anisotropic NPs com- Polymers 2022, 14, 976

pared to functionalized NPs. In addition, Zhang (2015) et al. studied the ability of mesoporous hydroxyapatite (M-HA) and hydroxyapatite (HA) to adsorb proteins [50]; when these materials were soaked for a prolonged time in bovine serum albumin (BSA) solution, the adsorption amount of BSA increased to reach the saturated adsorption of M-HA due to its high specific area and mesoporous structure. They also studied the adsorption and release behavior of M-HA and HA in different pH environments. With decreasing pH value, the adsorption capacity of both groups (M-HA and HA) of BSA showed an upward trend; an alkaline pH of 8.4 resulted in greater charge repulsion between BSA and particles, which is not conducive to adsorption. In the subsequent release test, the BSA release duration of M-HA and HA in the alkaline environment was longer than that in the neutral/acidic environment, and the initial burst release slowed down. He (2015) et al. compared the BSA adsorption and release behavior of mesoporous HANPs (M-HANPs) and solid HANPs [51] and found that the BSA loading in M-HANPs (182 mg/g) was greater than in solid HANPs (102 mg/g) because of M-HANPs having higher specific surface area and larger pore volume than solid HANPs. By contrast, solid HANPs have no internal mesoporous structure, so BSA is mostly adsorbed on the outer surface, resulting in limited load-carrying capacity. In the adsorption mechanism of apatite, intermolecular forces, such as van der Waals, electrostatic, hydrogen bonding, and hydrophobic attractions, mainly lead to adsorb proteins. BSA has a better adsorption affinity for Ca2+ sites on the surface of apatite. The amount of BSA adsorbed on the surface of solid HANPs is less than that of M-HANPs, and the absorption is effectively increased through the additional mesoporous structure. In the release test, M-HANPs will limit the outward diffusion of the drug due to the mesoporous structure, thereby prolonging its release time. Figure 1 shows that the bioactive surface of HANPs mimics the surface of natural bone to facilitate more protein adsorption through pore adsorption, surface charge adsorption, and covalent adsorption of ions by effectively controlling drug release through pH changes in the implanted environment.

Figure 1. Schematic diagram of the adsorption and attachment factor mechanism of porous HA nanorod [52].

2.2. Effect of HA Structure on Drug Adsorption The biological properties of biomaterials are greatly affected by their protein adsorption properties, which are related to the structures and properties of biomaterials and proteins. HA nanoparticles with a mesoporous structure (M-HANPs) could be an ideal drug carrier due to its physicochemical properties, good bioactivity, and bioabsorption. Templated hydrothermal synthesis is the most common and easiest method used to prepare M-HAs [53–60]. In contrast to solid HANPs, the hollow mesopores in M-HANPs possess numerous pore structures, which help increase the specific surface area for more efficient adsorption of chemotherapeutic drugs via electrostatic interactions. In addition, the hollow mesopores in M-HANPs can respond to changes in pH and burst release in the initial stage under acidic conditions, which limits their application in the field of drug delivery [53]. The inner space of M-HANPs contains a large number of voids, which can serve as

drug storage sites; at the same time, the hollow shell acts as a permeation barrier to limit the burst release of drugs [28,54–56]. Munir et al. (2018) compared the effect of hollow and solid M-HANPs loaded with ciprofloxacin (CFC) [57]. The pore size distribution of the hollow M-HANP is narrow, about 3.6 nm, while the pore size distribution of the solid MHANP is wider, about 22.58 nm. The specific surface area difference between hollow and solid M-HANPs was nearly 16 times, and the kinetics of CFC release was of zero-order. The results reconfirmed that the large specific surface area and porous structure of MHANP resulted in the high drug loading capacity, which could effectively improve the drug utilization. Safi et al. (2018) synthesized M-HANPs with CaCO3 through a low-temperature solvent method and explored their ability to carry ibuprofen (IBU) [58]. Micropores and mesopores coexist in the HA structure with a specific surface area of 85 m2/g, which is more conducive to drug adsorption. The initial release of IBU was relatively low within 5–180 min and peaked after 4 h, which was complemented by the release of IBU adsorbed on the HA surface followed by the release in the pores of HA; hence, the porous structure can significantly prolong the drug release time, and the release rate is about 50% IBU impregnation after 12 h of release. Chen (2020) developed hollow hierarchical MHA/poly(N-isopropylacrylamide- co-acrylic acid) and gold nanorods through electrostatic self-assembly for multi-stimuli remotely controlled drug delivery to evaluate the benefits of carrying doxorubicin hydrochloride (DOX) [53]. The results showed excellent sustained release and multiple responsive release characteristics under near-infrared light and pH 4.5. This controllable intelligent drug carrier can be applied to different drug delivery routes and has a good prospect in the field of photothermal chemotherapy. Figure 2 shows the possible mechanisms of drug adsorption by carboxylic acid to the surfacemodified HANPs, and the drug is easily carried for the electrostatic attraction of drug and modified HANPs.

Figure 2. Schematic diagram of drug adsorption on the surface-modified HANPs. (−: negatively charged biding sites on surfaces of modified HANPs; D: active molecule of drugs.)

Benedini (2019) et al. investigated the adsorption and release of HA by using two active drugs, namely, ciprofloxacin (CIP) and IBU. The charged CIP molecules mainly interact with Ca2+ and PO43− in HA to achieve adsorption effect; IBU produces electrostatic adsorption with HA modified by amino acid L-arginine. CIP had the highest adsorption concentration at pH 6, but the release percentage was the lowest; while IBU had the highest adsorption concentration at pH 7.4, and the release percentage was the lowest at pH 6. The adsorption kinetics of both drugs belonged to the Avrami’s model [36]. Lee (2010) et al. studied the effect of charge functionalization of the HA surface on the loading of curcumin by characterization of carboxylic acid-functionalized HA (CA-HA) [59]. The HA crystal length shortened with increasing number of carboxylic groups, similar to the report of Ishihara (2019) et al. [60]; that is, the strong interaction between acidic groups and Ca2+ reduced the free concentration of Ca2+ during HA formation, resulting in shrinking of HA crystals and decreasing particle crystallinity. The electrostatic interaction between

curcumin particles and CA-HA occurs mainly through opposite charges, and CA-HA exhibits better anti-cancer effect. Researchers still face challenges in processing polymer/NP composites to convert into nanofibers to maximize their practical applicability. Table 1 summarizes the differences in the structures of HANPs with and without mesopores as templates in carrying proteins/drugs for biomedical applications. Table 1. Related applications of different types of HANP structures as a template in carrying proteins/drugs. HANP Structures

Highlights and Potential Clinical Applications Comparing the effects of different types of HA modified with cetyl Solid (non-porous) hydroxpyridine chloride on the interaction with pepsin A, HANPs have yapatite nanoparticles Pepsin A higher enzymatic activity (18.45%) than microscale. HANPs with sur(HANPs) face modification can improve their use in biomedical applications potential. The adsorption capacity of M-HANPs in acidic environment (pH 4.7) Mesoporous hydroxyapBovine serum albumin was higher than that of micro-HA particles. In alkaline environments atite nanoparticles (M(BSA) (pH 8.4), they have smaller bursts and flatter release profiles, which HANPs) can be used for targeted drug delivery and bone therapy. Fetuin has the ability to inhibit the growth of M-HA nanocrystals to form dumbbell shaped, mesoporous structure, and large surface area. Mesoporous hydroxyap- Fetuin from serum pro- M-HAs of rod-like crystal size (235–515 nm) with inner mesopores atite rod-like nanocrystals (21–31 nm) can load more drugs and sustained-release drugs, which tein is beneficial to the field of drug delivery and sustained-release as drug delivery vehicles. The hollow mesoporous structure of M-HANPs has high biocompatiHollow mesoporous hybility and good drug loading capacity, the drug loading rate is inDoxorubicin (DOX) droxyapatite nanoparticles creased from 17.9% to 93.7%, and has excellent drug nanocarrier performance as carriers of large pharmaceutics. Compared with solid HANPs, M-HANPs have higher specific surface Solid and mesoporous hyarea and high drug loading, and have greater application potential in Ciprofloxacin droxyapatite nanoparticles the field of drug delivery. Therefore, M-HANPs can potentially be used in smart drug delivery systems. Carboxylic acid surface modification of HANPs can enhance the adFunctionalization of hysorption of curcumin and improve its drug availability. Curcumincurcumin nanoparticles droxyapatite nanoparticles modified HANPs have better anticancer activity and have good potential in the field of medical regeneration.

3. Recent Strategies for Compounding Natural and Synthetic Polymers with HA Regenerative tissue is composed of multiple proteins and polysaccharides that assemble into an organized network that provides structural support to cells. Natural polymers, e.g., collagen, cellulose, gelatin, silk fibroin, keratin, chitosan, alginate, etc., are commonly used for scaffolds and have the potential advantage of supporting cell adhesion and function [61–64]. The diversity of HA/polymer composites as scaffold materials has been driven by the structural composition and function of polymers as well as immunogenicity and pathogen transmission. This review summarizes the most commonly used HA (especially for HANPs)/polymer composites for biomedical applications. 3.1. Electrospun Composites of HANPs/Organics Electrospinning is a direct, inexpensive, and unique method for producing novel fibers with diameters of 100 nm and even smaller [65–74]. In fibrous membranes, polymer solutions, suspensions of HANPs containing drug and protein additives are electrospun in an electric field (Figure 3), since electrospinning is a simple, convenient, and low-cost nanofiber fabrication technique. Generally, a high-voltage electric field is used to pull the electrospinning colloidal solution containing organic solutes, vaporized solvents and

HANPs additives in the syringe into fibers, so that the solvent is completely volatilized between the needle and the collector to obtain a HANPs composite fibrous membrane [65–68]. To achieve the desired viscosity for electrospinning, and to adjust the voltage, flow rate, and spinning distance to prepare HANPs composite fiber membranes, it is necessary to carefully tune the dispersed HANPs in the polymer matrix [69]. Watcharajittanont (2020) et al. electrospun TiO2, HANPs, and polyurethane (PU) into fibrous membranes for maxillofacial and oral surgery [70]. Sani (2021) et al. incorporated different concentrations of HANPs into chitosan (CS) and poly (ε-caprolactone) (PCL)/CS graft copolymers to fabricate bone-like fibrous scaffolds [71]. Wang (2021) et al. added HANPs into CS/gelatin to form reinforced-polyelectrolyte complex nanofibers as encapsulation for controlled release of tetracycline hydrochloride (TCH) [72]. Chuan (2020) et al. prepared a composite stereoscopic nanofiber membrane through electrospinning using a poly(lactic acid) (PLA) matrix and uniformly dispersed HANPs [73]. Chen (2019) et al. introduced coaxial electrospinning technology to prepare HANPs/gelatin-chitosan core– shell nanofiber for biomimetic composite scaffolds [74].

Figure 3. Fiber-based membranes were prepared by electrospinning simulated polymer composite HANPs.

3.2. 3D Printing of Scaffolds for Tissue Engineering 3D printing technology follows the additive principle, that is, point by point and layer by layer, to create solid objects by computer-aided modeling (Figure 4). Compared with traditional production methods, 3D printing has the advantages of fast molding speed, high precision, and suitability for producing complex shapes. In vivo application, irregular defect sections and intricacies of simulated tissue can be assembled by precise positioning [75–77]. The HA granules smaller than the nozzle size are mixed with polymers and polymerized by adding a binder or by curing; the printing parameters (shape, size, pores, etc.) are set to prepare a 3D structural scaffold for the desired application. Iglesias-Mejuto (2021) et al. prepared 3D-printed alginate aerogel scaffolds containing HANPs through combination of 3D printing and supercritical CO2 drying for bone regeneration [78]. Their results showed that HANPs and CaCl2 (the major provider of Ca2+ concentration) determined the scaffold texture. Cestari et al. (2021) fabricated a composite of bioderived PCL and HANPs by 3D printing to obtain porous scaffolds for bone regeneration [79]. Wei (2021) et al. used 3D-printed HA microspheres enhanced with poly (lactic-co-glycolic acid) (PLGA) to evaluate the efficiency for bone regeneration scaffolds [80]. Chen (2019) et al. investigated the 3D printing of composite scaffolds composed of HA and gelatin, CS, and carboxymethyl cellulose (CMC) [81]. Yeo (2021) et al. studied 3Dprinted poly(glycolic acid)/HA composite scaffolds to promote bone regeneration [82]. The most important advantage of 3D-printed scaffolds is that 3D scaffolds can be used as tissue models to replicate the structural complexity of living tissues. Therefore, not only

the biomaterials used but also the macroscopic, microscopic, and nanostructures of scaffolds are crucial. The 3D-printed bone scaffold containing HANPs in a biopolymer-based bio-ink formulation may provide a viable option for promoting patient specific tissue regeneration through precisely control of scaffold structure and composition.

Figure 4. Schematic diagram of 3D printing to prepare polymer composite HANP scaffolds.

3.3. Freeze Drying to Prepare Scaffolds Freeze drying is the best drying technique for heat-sensitive food materials over other conventional drying techniques. During the process, ice evaporates directly without forming a liquid phase (sublimation) due to reduced pressure (Figure 5). However, freeze drying is an expensive and time-consuming technique, which limits its use in drying heatsensitive and high-value products. The porous scaffold obtained by this method has the characteristics of high porosity and interconnected pores, but the pore distribution is relatively uneven due to the size and distribution of ice crystals. During freeze drying, the solvent initially solidifies, allowing the polymer and HA to enter the interstitial spaces. The frozen mixture is then lyophilized using a freeze dryer, where the ice solvent is evaporated [30,83]. Ma (2021) et al. prepared biomimetic gelatin/chitosan/polyvinyl alcohol/HANP scaffolds for bone tissue engineering by freeze drying [84]. Xing (2021) et al. prepared chitin– hydroxyapatite–collagen composite scaffolds for bone regeneration by freeze-drying [85]. Pottathara (2021) et al. [86] prepared gelatine/collagen/HANP scaffolds by unidirectional freeze-casting. Kane (2012) et al. investigated the effect of HA addition and morphology on the structure and compressive mechanical properties of freeze-dried collagen scaffolds [87]. Brahimi (2022) et al. prepared highly porous chitosan/HA scaffolds through freeze gelation by varying the HA content [88]. Feroz (2021) et al. developed a novel hydroxypropylmethyl cellulose (HPMC) crosslinked keratin scaffold with HA as the main inorganic component for alveolar bone regeneration by freeze-drying technology [89]. By incorporating HANPs into the polymer matrix of dextran/chitosan, El-Meliegy (2018) et al. realized a novel composite scaffold by freeze-drying technique and determined the effect

of HANPs on scaffold morphology and mechanical properties [90]. They found the presence of HANP as a reinforcement can noticeably enhance the elastic modulus and compressive strength of the HANPs composite scaffolds.

Figure 5. Schematic diagram of the preparation of porous scaffolds of polymers composite HANPs prepared by freeze-drying.

3.4. Other Techniques All of the above properties enhance the technology of HANPs/polymers for biomedical applications, and many other strategies are available. For example, Nabavinia (2019) et al. investigated the effects of HANPs–alginate–gelatin-based microcapsules as a cell adhesion molecule and HANPs as an osteoconductive component on the properties of alginate-based hydrogels and evaluated the behavior of microcapsule osteoblast-like cells by using factorial experimental design technique [91]. Silva (2022) et al. processed polyvinylidene fluoride (PVDF) and HA composite filaments by twin-screw extrusion with different processing screw fin angular speeds [92]. Wenzhi (2021) et al. prepared microspheres of HANPs and poly (lactide-co-glycolide) nanocomposite for bone repair by a novel airflow shearing technology and evaluated its potential for clinical application as in vivo bone repair fillers [93]. Mahmoud (2020) et al. produced alginate/HANPs composite scaffolds by utilizing fish bones as a biosource for HANPs [94]. Their 3D porous scaffolds were fabricated using a sponge polymeric approach and then coated with alginate to enhance biodegradability and osteoconductivity. 4. Polymers–HA Composite as Carriers for Drug-Sustained Release In summary, HA has the characteristics of adsorbing drugs and biocompatibility and is an ideal drug carrier material. However, the initial release rate of the drug is very fast due to the weak interaction between the drug and the HA particles. In addition to its excellent mechanical properties and surface functionality, polymers–HA composite can be used to prolong drug release, making HA/polymer composites suitable as carriers for drug-sustained release [95]. Different carrying targets (such as antibiotics, anti-inflammatory, and anti-cancer drugs, natural extracts, growth factors, etc.) can be added to achieve the local and special needs for clinical surgical treatment. For example, in Figure 6, HANPs/polymer composites of different structures can be used as carriers of drugs, proteins, or antibacterial agents.

Figure 6. Appearances of (a) electrospun film; (b) freeze-dried scaffold; (c) freeze-dried beads (d) microspheres, and (e) electrospray nanospheres.

4.1. Membrane Form Eskitoros-Togay (2020) et al. incorporated different ratios of HANPs and curcumin into the same PCL/poly (ethylene oxide) (PCL/PEO) mixed matrix to form membranes by electrospinning. The encapsulation efficiency of curcumin in the electrospun membranes was 86–94%. The fiber membrane containing 0.3% HANPs showed a gradual increasing trend in the first hour of release and only reached 43% of curcumin released from the release time to the eighth hour, indicating that the controlled release of curcumin can be achieved in a simulated environment to prolong the action of the drug after implantation [96]. By varying the weight ratio of sodium alginate and gelatin (A/G = 40/60, 50/50, and 60/40) and adding different concentrations of HANPs (1, 2, 5, 10, and 20% w/w) to the film solution, Türe (2019) et al. explored whether the addition of HANPs alters the physical, mechanical, thermal, and antimicrobial properties of the films. In addition, tetracycline hydrochloride (TH) was chosen as a model to study drug release in water. Their results showed that the swelling rate and weight loss decreased as the amount of alginate. Membrane structures with high alginate content were denser compared to the increased amount of HA that resulted in rougher surfaces. Films with lower tensile and elastic modulus values with greater than 1% HANPs for A/G = 50/50 and 60/40 [97]. The amount of TH released decreased with increasing amount of HA, as the addition of HA acted as a barrier and reduced the drug release. In this study, swelling behavior and TH release have similar patterns. Prakash (2019) et al. fabricated HANPs-incorporated polyvinyl alcoholsodium alginate (PVA-SA) membranes for controlled release of the antibiotic amoxicillin to treat subosseous periodontal defects [98]. In this study, the polymer tends to degrade, leading to drug release, and SA dissolves faster in aqueous systems compared with PVA

at room temperature; therefore, when SA degrades in the polymer matrix, the drug molecules tend to detach from the membrane and acts on the infected area. The result showed that the amount of amoxicillin released 43% of the drug on day 3, 72% on day 6, and 87% on day 10, suggesting that the drug release from these composite membranes were sustained. Ramírez-Agudelo (2018) et al. released doxycycline (Dox) and HANPs from biodegradable polymer composite nanofibers of PCL/gelatin for local drug delivery [99]. Dox and HANPs were encapsulated at various PCL/Gel ratios (70:30, 60:40, 50:50 wt%). They prepared Dox/HANPs-loaded PCL-Gel composite fibers by electrospinning. The release kinetics of Dox can be shown in two phases: in the first phase, all scaffolds exhibited about 60% burst effect release in the first hour; in the second release stage, the remaining loaded drug can be released within 55 h. Baldino (2018) et al. studied the silver-loaded HANPs being incorporated into PVA membranes obtained by supercritical CO2 (SC-CO2) assisted phase inversion [100]. Their results show that HA-Ag NPs loaded in PVA membranes were more active than the HANPs alone. The bactericidal results show that the Ag+ concentration in the HA-Ag NPs can be reduced from 22 ppm to 11 ppm, which has a bacteriostatic effect on E. coli, and the Ag+ in the composite membranes can prolong and control its release behavior, which can be used in biomedicine, coating and filter applications. 4.2. Scaffold Form Kim (2004) et al. prepared HA porous scaffolds by polymeric reticulate method with HA-PCL composite after embedding with the antibiotic drug TCH [101]. The HA/PCL ratio had a strong effect on release. In a short period (<2 h), about 20–30% of the drug was released. However, the release rate persisted for a long time and was highly dependent on the extent of coating HA/PCL dissolution. Zhang (2021) et al. prepared 3D scaffolds by using PCL/PEO/HA with different HA concentrations by direct ink writing (DIW) [102]. Vancomycin (VAN) was incorporated into composite scaffolds, and the drug release properties of the composites were investigated. The release kinetics of PCL/PEO/HA samples containing low and high VAN loadings (3% and 9% w/w) were determined in vitro. The VAN-loaded PCL/PEO/HA scaffolds exhibited a first-order immediate release, i.e., a large burst of release within a half hour. In addition to drug concentration and drug–polymer interactions, scaffolds with higher porosity and surface/volume ratio have faster VAN release profile, which can be used for hemostasis and anti-inflammation related to bone tissue applications. Martínez-Vázquez (2015) et al. fabricated Si-doped HA/gelatin porous scaffolds at moderate temperatures by using a rapid prototyping system and analyzed the release profiles of vancomycin from different scaffolds [103]. Less than 30% of vancomycin was released from the scaffold within 1 h, and the antibiotic release continued for 8 h. Hu (2014) et al. used the anti-inflammatory drug IBU to study the drug release behavior of HA/poly(l-lactic acid) (PLLA) nanocomposite scaffolds [104]. The IBU loaded in the nanocomposite exhibited a sustained release curve, and the release kinetics followed the Higuchi model with a diffusion process. Zhang (2012) et al. prepared a novel vancomycin (VCM)-loaded M-HA/CS composite scaffold by freeze-drying and used it for in vivo drug release and antibacterial studies [105]. The results indicated that drug-VCM loaded M-HA/CS composites can release VCM for a long time after implantation in vivo and exhibit effective antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA). Liang (2021) et al. prepared a composite hydrogel scaffold of HA and sodium alginate (SA) by using 3D printing [106]. Additives naringin (NG) and calcitonin generelated peptide (CGRP) were used as osteogenic factors for the fabrication of drug-loaded scaffolds. The HA/SA scaffold can continuously and stably release NG and CGRP until the 21st day, and the drug was mainly released from the large pores of the scaffold to achieve the purpose of bone regeneration.

4.3. Spherical Form Bi (2019) et al. investigated the drug loading behavior on HANPs, HANPs/ SA, and HANPs/SA/CS composite [107] and the drug release behavior of doxorubicin hydrochloride (Dox·HCl)-loaded HANPs/SA/CS microspheres for drug delivery system in phosphate-buffered saline (PBS) solutions with different pH values (pH 7.4, 6.5, and 5.0). The drug loading and encapsulation efficiency of HANPs were 5.9% ± 0.6% and 11.8% ± 1.2%, respectively, which were lower than those of the composite microspheres. This finding might be attributed to the weak electrostatic interaction between HANPs and drug molecules. The 3D network structure of the microspheres helps to load more drugs because the drug molecules are not only absorbed into the 3D network structure of the microspheres but also on the surface of the microspheres. However, the drug loading of HANPs/SA microspheres is higher than that of HANPs/SA/CS microspheres because their surface is coated with a thin film; the film may become an obstacle for drug molecules to be absorbed into the internal structure of the microspheres. The Dox-loaded microspheres showed faster drug release properties with decreasing environment pH. HA and CS were degradable in acidic media, and their different release behavior types were attributed to the different levels of degradability under various medium conditions. Dox-loaded microspheres adopt slow-release behavior, which can be attributed not only to electrostatic interactions between hydroxyl and amine groups but also to the uniform dispersion of HA nanoparticles inside the microspheres and on the surface. Xue (2018) et al. prepared polyvinyl alcohol (PVA)/HA composite microspheres with different HA contents by in situ synthesis and the synergistic effect of emulsification–crosslinking [108]. In this study, vancomycin hydrochloride (VH) was selected as a model drug to embed in microspheres by immersion. The PVA microspheres have larger swelling degree after proper crosslinking with glutaraldehyde through hydrogen bonding or ionic interactions and have good drug VH encapsulation efficiency and VH loading capacity. He (2021) et al. designed and fabricated microspheres and scaffolds assembled using HA and vancomycin hydrochloride (VH)-loaded polytrimethylene carbonate (PTMC) and PLLA core/shell microspheres [109]. Combining drugs, active growth substances, and CS in the same microsphere carrier provides sustained long-term release. The drug loading (original encapsulated drug = 2.6 mg) and drug loading efficiency (200 mg) of VH in the microspheres were 1.52 ± 0.06 mg and 58.3% ± 3.9%, respectively. Zhang (2010) et al. prepared pH-sensitive SA/HA nanocomposite beads in sol–gel as drug delivery vehicles, with iclofenac sodium (DS) as a model drug. Factors affecting the swelling behavior, drug loading, and controlled release behavior of SA/HA nanocomposite microspheres were studied in detail. Compared with pure SA hydrogel beads, the SA/HA-DS nanocomposite beads prepared under optimal conditions can prolong the release of DS up to 8 h. Calasans-Maia (2019) et al. prepared alginate-encapsulated nanobicarbonate hydroxyapatite (CHA) microspheres for topical delivery of minocycline (MINO) to inhibit the growth of Enterococcus faecalis [110]. The amount of MINO adsorbed on the CHA powder depends on the initial concentration of MINO in the solution, the quality of CHA, and the pH of the solution. Adsorption experiments were performed using 1.5 mg/mL MINO in PBS buffer solution (pH = 7.4) containing 50 mg/mL CHA powder. After 24 h, the amount of antibiotic loaded on the CHA powder was 25.1 ± 2.2 µg MINO/mg CHA. The MINO loss of CHA during microsphere processing was about 40%. The MINO release profile of CHA microspheres loaded with 15.1 ± 1.4 µg MINO/mg CHA in PBS buffer was evaluated. A rapid release of approximately 60% of the initially loaded MINO (9.1 µg MINO/mg CHA) was observed within the first 24 h, and the remaining 6.0 µg MINO/mg CHA sustained release was observed over 10 days. Padmanabhan (2018) et al. prepared core–shell nanocomposites with gum–acacia (GA) as shell and HANPs as core for drug delivery and tissue engineering and studied the drug release behavior of naringenin [111]. The uneven distribution of naringenin in the HANP matrix may result in a rapid release pattern. By contrast, in the case of GA-HA, the colloidal nature of GA helps to bind to naringenin efficiently, allowing for better distribution of the drug throughout the core–shell nanocomposites. Electrospinning, 3D

printing, and freeze drying are commonly used to composite HANPs into thin films, regenerated membranes, scaffolds, microspheres, and coatings; drugs can also be loaded according to the composite structure to meet different clinical applications. 4.4. Coating Prasanna (2018) et al. synthesized HANPs as nanocarriers for sustained release of the antibiotic amoxicillin for treatment of bone infections. Nanoparticles were then coated on PVA and SA in a layer-by-layer spray coating. Layer-by-layer coating of HANPs/PVA/SA resulted in sustained release of amoxicillin, which was observed for 30 days [112]. Bose (2018) et al. investigated the influence of PCL coating on alendronate drug release kinetics in vitro [113]. The results showed that PCL coating would minimize the burst release of alendronate from plasma-sprayed Mg-doped HA coated commercially with pure titanium (cp-Ti). In the absence of PCL coating, about 75% of alendronate was released within the first 12 h. The samples with 2 and 4 wt% PCL coatings exhibited slower burst release, with values of 34% and 26%, respectively. After 24 h, the samples without PCL coating released >75% alendronate. The samples with PCL coating released about 50% alendronate. Kong (2016) et al. used the anticancer drug DOX as a model drug to load into the resulting HANPs-polyethyleneimine (PEI)-hyaluronic acid (HyA) nanoparticles [114]. DOX@HANPs-PEI-HyA nanoparticles were subjected to buffer solutions with different pH values at 37 °C to examine the DOX release behavior in vitro. The cumulative DOX release percentage of DOX@HANPs-PEI-HyA at pH 7.4 was only 23% over 48 h, while more than 88% DOX release was observed at pH 5.0. Under acidic conditions, the amino group of DOX was protonated, which weakened the adsorption between HANPs and DOX. Meanwhile, PEI was swollen in the acidic environment due to the protonation of amine groups. Therefore, these reasons strongly promote DOX diffusion out of DOX@HANPs-PEI-HyA under acidic conditions. Therefore, this pH-responsive drug release property of DOX@HANPs-PEI-HyA nanoparticles makes it promising for cancer therapy due to the weak acidity of tumor tissues and tumor cells. Numerous studies have highlighted the role of HANPs in promoting the regeneration of tissues with polymers, and Table 2 briefly summarizes the different polymer-HA composite morphologies mentioned above. Table 2. Characteristics and possible clinical applications of different types of polymer-HA composites. Biomolecules with Different Types of Appearance

The composite nanofibers have long-lasting antibacterial TCH/HANPs/CG core–shell nano- Tetracycline hydrochlo- function, good biocompatibility, and high mechanical fibers strength, and are suitable for wound dressings and drug ride (TCH) delivery systems. The diameter of the composite microspheres is about 250 μm. When the content of HANPs was 20% and 40%, respectively, it could promote the mineralization and osteo− HANPs/PLGA microspheres genic differentiation of MC3T3-E1 cells, and had good clinical application potential in bone tissue engineering and bone implantation. The addition of HANPs will make the surface of the composite film rougher and effectively improve the thermal HANPs-containing alginate–gelatin Tetracycline hydrochlo- stability. In addition, it can reduce the initial burst release composite films ride (TCH) of the drug. The polymer-HA composite film can be used not only for biomedical applications, but also for food packaging. Polycaprolactone/ polyethylene oxThe composite scaffold with HA content of 65% had the Vancomycin (VCM) ide/ hydroxyapatite 3D scaffolds best wettability and mechanical properties, but adding too

much HA would affect the mechanical properties of the polymer-HA composite. The drug release showed an initial burst, and the 3D scaffold with antibacterial activity was suitable for bone tissue engineering applications. A chitosan (CS)-coated polytriTwo active molecules, OA-HA and VH, can be released methylene carbonate (PTMC)/polylacthrough the pores. In addition to facilitating osteoblast adtic acid (PLLA)/oleic acid-modified vancomycin hydrochlohesion, CS coating can also control the release behavior of hydroxyapatite (OA-HA)/vancomycin ride (VH) the OA-HA to stimulate the proliferation of osteoblasts, hydrochloride (VH) microsphere scafwhich is expected to be used in bone tissue engineering. fold

5. Conclusions Apparently, the large number of pores in M-HA can effectively increase the drug loading and slow down the initial burst release. In addition, surface modification can effectively improve the loading effect of HA on specific active molecules, further increasing the versatility of HA. The preparation strategy of HANPs composite polymer will be selected according to different clinical requirements and functions to achieve multifunctional purpose (such as wound dressing, bone tissue engineering, etc.). When the HA composite polymer is loaded with proteins/drugs, the release amount and rate are also different due to different structures and contact environments. For example, the 2D contact area of the membrane/film is lower than that of the 3D scaffold and microspheres. Drugs released more easily due to the inherent porosity of the microspheres due to the larger specific surface area and the expansion of the scaffold after implantation. In addition, the degradation rate of the polymers, the pH value of the drug release environment, the characteristics of the drug itself, such as lipid (fat)-soluble or water-soluble, and the bond between the drug and HA and macromolecules, affect the release. The protein/drugcarrying HANPs have large changes in physical and chemical properties due to changes in surface conditions, which will affect their application ability as carriers to introduce functions into repair sites. Therefore, further selection of biomolecules, proteins/drugs, preparation methods and structures is required to prepare HA-templated carriers.

📖 中文全文 Chinese Full Text

中文

# 综述

## 用于生物医学应用的羟基磷灰石杂化有机复合材料作为药物或蛋白载体的研究进展

**Ssu-Meng Huang 1,†, Shih-Ming Liu 1,†, Chia-Ling Ko 1 and Wen-Cheng Chen 1,2,3,\***

1 先进医疗器械与复合材料实验室,纤维与复合材料系,逢甲大学,台中407,台湾 2 高雄医学大学药学院香料与化妆品科学系,高雄807,台湾 3 高雄医学大学口腔医学院牙科医疗器械与材料研究中心,高雄807,台湾

\* 通讯作者:wencchen@mail.fcu.edu.tw † 这些作者对本工作做出了同等贡献。

---

**摘要:** 羟基磷灰石(HA),尤其是纳米羟基磷灰石(HANPs),具有优异的生物活性、生物降解性和骨传导性,因此被广泛用作临床应用中药物递送的模板或添加剂,如牙科和骨科修复。由于HA晶体在优先生长方向上呈原子各向异性分布,特别是纳米级棒状/晶须状形貌,HA通常可作为多种物质的良好载体。HA具有生物相容性,适用于医学应用,但大多数由HANPs载带的药物存在初始突释现象。在HA作为载体的吸附机制中,比表面积、孔径和孔隙率是主要影响吸附量和释放量的重要因素。目前,许多研究已开发出具有靶向效应、多孔结构和高孔隙率的HA药物载体。本综述主要讨论了HA作为载体的结构对活性分子吸附和释放的影响,然后重点探讨了不同类型聚合物-HA复合材料的优势和效果,以重新审视蛋白质/药物的负载与释放行为及相关潜在临床应用。本文献综述可分为三个主要部分:(1)HA与药物的相互作用及吸附机制;(2)HA/有机复合材料的优势及应用领域;(3)多功能HA复合材料在不同环境中的负载与药物释放行为。本工作还介绍了HA作为药物载体的最新进展和未来前景。

**关键词:** 羟基磷灰石;纳米粒子;复合材料;药物释放;蛋白质;模板;载体;组织工程;支架

---

## 1. 引言

生物陶瓷是用于修复或重建人体硬组织受损部分的生物相容性陶瓷、玻璃材料或陶瓷/玻璃复合材料[1]。经过数十年的研究,人们一直关注生物陶瓷的机械性能和生物相容性[2],而当前的趋势是向具有额外治疗功能(如抗菌和抗肿瘤)的功能性聚合物-生物陶瓷复合材料发展[3]。羟基磷灰石(HA)具有六方晶体结构,分子式为Ca₁₀(PO₄)₆(OH)₂,HA纳米粒子(HANPs)的结构具有两个不同的结合位点。例如,HANPs两端带负电荷的磷酸根离子,侧面带正电荷的Ca²⁺阳离子[4-7]。HA是人类骨骼的重要矿物质,骨骼由70%的低结晶或无定形磷灰石、30%的胶原蛋白和骨髓细胞组成[8-12]。目前,磷灰石的制备方法主要包括湿法[13-15]、干法[16-18]、溶胶-凝胶法[19-21]、生物组织合成法[22-24]、水热法[25-27]和冷冻干燥法[28-30]。HA具有良好的生物活性、生物相容性和无毒性,广泛用于骨骼和牙齿等硬组织的填充和修复[31-33]。当HA主要作为载体时,特别是以HANPs形式,它可以携带蛋白质、生长因子、抗生素、抗炎药物、肿瘤药物等[34-37],从而缩短治疗时间,实现局部缓释,并引导组织再生。HANPs的吸附能力直接取决于其比表面积、形貌和水合状态,这些通常由pH值和电解质浓度调节[38]。对于药物递送应用,HANPs中的孔隙率和孔隙分布对于确定药物负载能力、药物递送效率和释放动力学非常重要[39]。由于带电基团和极性基团通过形成离子对、氢键和其他不太特异性的静电相互作用赋予蛋白质重要特性,HANPs的表面电荷可以通过氢键或静电相互作用控制蛋白质结合,从而提供蛋白质分子与HANPs表面之间的结合位点[40]。因此,HANPs中的钙阳离子(Ca²⁺)和磷酸根阴离子(PO₄³⁻)可用作蛋白质的优先结合位点[41,42],蛋白质-矿物离子复合物可通过特定的配体相互作用形成蛋白质;例如,肽本质上能够通过螯合作用将Ca²⁺与羰基结合。

HANPs是一种与天然骨组织成分相似的磷酸钙化合物,具有优异的生物相容性、骨传导性、骨诱导性和成骨能力,因此被广泛应用于骨科和药物递送系统[36,43-45]。HANPs与天然和合成聚合物的复合有效解决了HANPs的问题,如高脆性、不可控的降解速率、较差的塑性和易团聚[46]。将HANPs复合到聚合物基质中进行加工的方法包括静电纺丝、三维(3D)打印、冷冻干燥等。这些杂化复合材料可形成所需的形貌,如编织线、薄膜、纳米纤维组成的膜、支架、微球或纳米珠以及喷涂涂层,以增强机械性能并适应目标应用[47,48]。除了结合HANPs外,这些复合材料还可以根据不同临床需求负载药物、磁性量子点或接枝生长因子或蛋白质。根据所得的HANP复合聚合物,这些杂化复合材料广泛用于各种医学领域,不仅限于骨组织的再生。

## 2. HA作为蛋白质/药物载体的模板

### 2.1. HANPs作为蛋白质吸附的载体

对于体内应用,纳米粒子(NPs)暴露于一系列生物分子中,这些生物分子在NPs周围形成一层"冠层",显著改变了NPs的表面特性。HANPs呈棒状,粒子沿c轴优先生长,具有强烈的不均匀电子分布和高比表面积。HANPs的形貌对调节离子释放具有显著影响,并进一步控制HANPs与蛋白质(胃蛋白酶A)的相互作用。例如,Kadu(2021)等人揭示了四种不同HANPs形貌及随后用氯化十六烷基吡啶(CPC)进行表面改性对蛋白质吸附的影响,以Cl⁻作为反离子[49]。结果表明,纳米粒子的形貌对反离子的释放有显著影响,导致蛋白质结构构象发生变化,从而控制其与蛋白质的相互作用。此外,由于改性HANPs与有效结合位点的结合效率,胃蛋白酶A的错误折叠顺序为短棒<长棒<球形<立方体NPs,其中各向同性的CPC与各向异性NPs的相互作用高于功能化NPs。此外,Zhang(2015)等人研究了介孔羟基磷灰石(M-HA)和羟基磷灰石(HA)吸附蛋白质的能力[50];当这些材料在牛血清白蛋白(BSA)溶液中浸泡较长时间时,由于M-HA具有高比表面积和介孔结构,BSA的吸附量增加至达到M-HA的饱和吸附。他们还研究了M-HA和HA在不同pH环境中的吸附和释放行为。随着pH值的降低,两组(M-HA和HA)BSA的吸附能力均呈上升趋势;碱性pH 8.4导致BSA与颗粒之间的电荷排斥增大,不利于吸附。在随后的释放测试中,M-HA和HA在碱性环境中的BSA释放持续时间比在中性/酸性环境中更长,且初始突释减缓。He(2015)等人比较了介孔HANPs(M-HANPs)和实心HANPs的BSA吸附和释放行为[51],发现M-HANPs中的BSA负载量(182 mg/g)大于实心HANPs(102 mg/g),因为M-HANPs具有更高的比表面积和更大的孔体积。相比之下,实心HANPs没有内部介孔结构,因此BSA主要吸附在外表面,导致负载能力有限。在磷灰石的吸附机制中,分子间作用力,如范德华力、静电作用、氢键和疏水引力,主要导致蛋白质吸附。BSA对磷灰石表面Ca²⁺位点具有更好的吸附亲和力。实心HANPs表面吸附的BSA量少于M-HANPs,通过额外的介孔结构可有效增加吸附量。在释放测试中,M-HANPs由于介孔结构会限制药物向外扩散,从而延长其释放时间。图1显示了HANPs的生物活性表面模拟天然骨表面,通过孔吸附、表面电荷吸附和离子的共价吸附促进更多蛋白质吸附,通过植入环境中pH值的变化有效控制药物释放。

**图1.** 多孔HA纳米棒吸附和附着因子机制示意图[52]。

### 2.2. HA结构对药物吸附的影响

生物材料的生物学特性受其蛋白质吸附特性的很大影响,而蛋白质吸附特性与生物材料和蛋白质的结构和性质有关。具有介孔结构的HA纳米粒子(M-HANPs)由于其良好的物理化学性质、生物活性和生物吸收性,可能成为理想的药物载体。模板水热合成法是制备M-HA最常用和最简单的方法[53-60]。与实心HANPs不同,M-HANPs中的中空介孔具有大量的孔结构,有助于增加比表面积,通过静电相互作用更有效地吸附化疗药物。此外,M-HANPs中的中空介孔可响应pH值变化,在酸性条件下初始阶段出现突释,这限制了其在药物递送领域的应用[53]。M-HANPs的内部空间含有大量空隙,可作为药物储存位点;同时,中空壳层作为渗透屏障,限制药物的突释[28,54-56]。Munir等人(2018)比较了负载环丙沙星(CFC)的中空和实心M-HANPs的效果[57]。中空M-HANPs的孔径分布较窄,约为3.6 nm,而实心M-HANPs的孔径分布较宽,约为22.58 nm。中空和实心M-HANPs之间的比表面积差异接近16倍,CFC释放动力学为零级。结果再次证实,M-HANPs的大比表面积和多孔结构导致高药物负载能力,可有效提高药物利用率。Safi等人(2018)通过低温溶剂法用CaCO₃合成了M-HANPs,并探索了其携带布洛芬(IBU)的能力[58]。HA结构中微孔和介孔共存,比表面积为85 m²/g,更有利于药物吸附。IBU在5-180 min内的初始释放相对较低,在4 h后达到峰值,这由吸附在HA表面的IBU释放补充,随后在HA的孔中释放;因此,多孔结构可显著延长药物释放时间,释放速率在12 h释放后约为50% IBU浸渍。Chen(2020)通过静电自组装开发了中空分级M-HA/聚(N-异丙基丙烯酰胺-共-丙烯酸)和金纳米棒,用于多刺激远程控制药物递送,以评估携带盐酸阿霉素(DOX)的益处[53]。结果显示在近红外光和pH 4.5条件下具有优异的缓释和多重响应释放特性。这种可控智能药物载体可应用于不同的药物递送途径,在光热化疗领域具有良好的前景。图2显示了羧酸对表面改性HANPs的药物吸附的可能机制,由于药物与改性HANPs之间的静电吸引,药物容易被携带。

**图2.** 表面改性HANPs上药物吸附示意图。(−:改性HANPs表面带负电荷的结合位点;D:药物的活性分子。)

Benedini(2019)等人通过使用两种活性药物环丙沙星(CIP)和IBU研究了HA的吸附和释放。带电的CIP分子主要与HA中的Ca²⁺和PO₄³⁻相互作用以实现吸附效果;IBU与用氨基酸L-精氨酸改性的HA产生静电吸附。CIP在pH 6时具有最高的吸附浓度,但释放百分比最低;而IBU在pH 7.4时具有最高的吸附浓度,在pH 6时释放百分比最低。两种药物的吸附动力学均属于Avrami模型[36]。Lee(2010)等人通过表征羧酸功能化HA(CA-HA)研究了HA表面电荷功能化对姜黄素负载的影响[59]。HA晶体长度随着羧基数量的增加而缩短,类似于Ishihara(2019)等人的报道[60];即酸性基团与Ca²⁺之间的强相互作用降低了HA形成过程中Ca²⁺的自由浓度,导致HA晶体收缩和颗粒结晶度降低。姜黄素颗粒与CA-HA之间的静电相互作用主要通过相反电荷发生,CA-HA表现出更好的抗癌效果。研究人员在加工聚合物/NP复合材料以转化为纳米纤维从而最大化其实际适用性方面仍面临挑战。表1总结了有和没有介孔的HANPs结构作为生物医学应用中携带蛋白质/药物的模板的差异。

**表1.** 不同类型的HANPs结构作为携带蛋白质/药物的模板的相关应用。

| HANP结构 | 亮点和潜在临床应用 | |---|---| | 实心(无孔)羟基磷灰石纳米粒子(HANPs)/胃蛋白酶A | 比较了用氯化十六烷基吡啶改性的不同类型HA与胃蛋白酶A的相互作用,HANPs具有比微米级更高的酶活性(18.45%)。表面改性的HANPs可改善其在生物医学应用中的潜力。 | | 介孔羟基磷灰石纳米粒子(M-HANPs)/牛血清白蛋白(BSA) | M-HANPs在酸性环境(pH 4.7)中的吸附能力高于微米级HA颗粒。在碱性环境(pH 8.4)中,它们具有更小的突释和更平坦的释放曲线,可用于靶向药物递送和骨治疗。 | | 介孔羟基磷灰石棒状纳米晶体/血清胎球蛋白 | 胎球蛋白具有抑制M-HA纳米晶体生长的能力,形成哑铃状、介孔结构和大表面积。具有棒状晶体尺寸(235-515 nm)和内介孔(21-31 nm)的M-HA可以负载更多药物并缓释药物,有利于药物递送和缓释作为药物递送载体。 | | 中空介孔羟基磷灰石纳米粒子/阿霉素(DOX) | M-HANPs的中空介孔结构具有高生物相容性和良好的药物负载能力,药物负载率从17.9%增加到93.7%,作为大分子药物载体具有优异的药物纳米载体性能。 | | 实心和介孔羟基磷灰石纳米粒子/环丙沙星 | 与实心HANPs相比,M-HANPs具有更高的比表面积和高药物负载量,在药物递送领域具有更大的应用潜力。因此,M-HANPs可潜在地用于智能药物递送系统。 | | 羟基磷灰石纳米粒子的功能化/姜黄素纳米粒子 | HANPs的羧酸表面改性可增强姜黄素的吸附并提高其药物可用性。姜黄素改性的HANPs具有更好的抗癌活性,在医学再生领域具有良好的潜力。 |

## 3. 天然和合成聚合物与HA复合的最新策略

再生组织由多种蛋白质和多糖组成,它们组装成有序网络,为细胞提供结构支撑。天然聚合物,如胶原蛋白、纤维素、明胶、丝素蛋白、角蛋白、壳聚糖、海藻酸盐等,通常用于支架,具有支持细胞粘附和功能[61-64]的潜在优势。HA/聚合物复合材料作为支架材料的多样性受到聚合物结构和功能以及免疫原性和病原体传播的驱动。本综述总结了最常用于生物医学应用的HA(特别是HANPs)/聚合物复合材料。

### 3.1. HANPs/有机物的静电纺丝复合材料

静电纺丝是一种直接、廉价且独特的方法,用于生产直径在100 nm甚至更小的新型纤维[65-74]。在纤维膜中,含有药物和蛋白质添加剂的HANPs悬浮液的聚合物溶液在电场中进行静电纺丝(图3),因为静电纺丝是一种简单、方便且低成本的纳米纤维制备技术。通常,使用高压电场将注射器中含有有机溶质、挥发性溶剂和HANPs添加剂的静电纺丝胶体溶液拉成纤维,使溶剂在针头和收集器之间完全挥发,从而获得HANPs复合纤维膜[65-68]。为实现静电纺丝所需的粘度,并调整电压、流速和纺丝距离以制备HANPs复合纤维膜,需要仔细调节聚合物基质中分散的HANPs[69]。

Watcharajittanont(2020)等人将TiO₂、HANPs和聚氨酯(PU)静电纺成纤维膜,用于颌面和口腔外科[70]。Sani(2021)等人将不同浓度的HANPs掺入壳聚糖(CS)和聚(ε-己内酯)(PCL)/CS接枝共聚物中,以制备类骨纤维支架[71]。Wang(2021)等人将HANPs加入CS/明胶中形成增强型聚电解质复合纳米纤维,作为盐酸四环素(TCH)控释的封装材料[72]。Chuan(2020)等人通过使用聚乳酸(PLA)基质和均匀分散的HANPs通过静电纺丝制备了复合立体纳米纤维膜[73]。Chen(2019)等人引入同轴静电纺丝技术制备了HANPs/明胶-壳聚糖核-壳纳米纤维,用于仿生复合支架[74]。

**图3.** 通过静电纺丝模拟聚合物复合HANPs制备的纤维基膜。

### 3.2. 用于组织工程支架的3D打印

3D打印技术遵循增材原理,即逐点逐层地通过计算机辅助建模创建固体物体(图4)。与传统生产方法相比,3D打印具有成型速度快、精度高和适合生产复杂形状的优点。在体内应用中,不规则缺陷部分和模拟组织的复杂性可以通过精确定位来组装[75-77]。将小于喷嘴尺寸的HA颗粒与聚合物混合,通过添加粘合剂或固化进行聚合;设置打印参数(形状、尺寸、孔隙等)以制备适用于目标应用的3D结构支架。

Iglesias-Mejuto(2021)等人通过结合3D打印和超临界CO₂干燥制备了含有HANPs的3D打印海藻酸盐气凝胶支架,用于骨再生[78]。他们的结果表明,HANPs和CaCl₂(Ca²⁺浓度的主要提供者)决定了支架的质地。Cestari等人(2021)通过3D打印制备了生物源PCL和HANPs的复合材料,获得用于骨再生多孔支架[79]。Wei(2021)等人使用3D打印的HA微球增强聚(乳酸-乙醇酸)(PLGA),评估其作为骨再生支架的效率[80]。Chen(2019)等人研究了由HA与明胶、CS和羧甲基纤维素(CMC)组成的复合支架的3D打印[81]。Yeo(2021)等人研究了3D打印的聚(乙醇酸)/HA复合支架以促进骨再生[82]。3D打印支架最重要的优势是3D支架可用作组织模型来复制活体组织的结构复杂性。因此,不仅所使用的生物材料很重要,支架的宏观、微观和纳米结构也至关重要。含有HANPs的生物聚合物基生物墨水配方的3D打印骨支架可通过精确控制支架结构和组成,为促进患者特异性组织再生提供可行的选择。

**图4.** 3D打印制备聚合物复合HANP支架的示意图。

### 3.3. 冷冻干燥制备支架

冷冻干燥是热敏性食品材料比其他常规干燥技术更好的干燥技术。在该过程中,冰在减压条件下直接蒸发而不形成液相(升华)(图5)。然而,冷冻干燥是一种昂贵且耗时的方法,这限制了其在干燥热敏性和高价值产品中的应用。通过该方法获得的多孔支架具有高孔隙率和相互连通孔的特征,但由于冰晶的尺寸和分布,孔隙分布相对不均匀。在冷冻干燥过程中,溶剂最初凝固,使聚合物和HA进入间隙空间。然后使用冷冻干燥机对冷冻混合物进行冻干,使冰溶剂蒸发[30,83]。

Ma(2021)等人通过冷冻干燥制备了用于骨组织工程的仿生明胶/壳聚糖/聚乙烯醇/HANP支架[84]。Xing(2021)等人通过冷冻干燥制备了用于骨再生甲壳素-羟基磷灰石-胶原蛋白复合支架[85]。Pottathara(2021)等人[86]通过单向冷冻浇铸制备了明胶/胶原/HANP支架。Kane(2012)等人研究了HA添加和形貌对冷冻干燥胶原蛋白支架结构和压缩力学性能的影响[87]。Brahimi(2022)等人通过改变HA含量通过冷冻凝胶化制备了高多孔壳聚糖/HA支架[88]。Feroz(2021)等人通过冷冻干燥技术开发了一种新型羟丙基甲基纤维素(HPMC)交联角蛋白支架,以HA作为主要无机成分,用于牙槽骨再生[89]。通过将HANPs掺入葡聚糖/壳聚糖的聚合物基质中,El-Meliegy(2018)等人通过冷冻干燥技术实现了新型复合支架,并确定了HANPs对支架形态和机械性能的影响[90]。他们发现HANP作为增强材料可显著提高HANPs复合支架的弹性模量和抗压强度。

**图5.** 通过冷冻干燥制备聚合物复合HANPs多孔支架的示意图。

### 3.4. 其他技术

上述所有特性增强了HANPs/聚合物在生物医学应用中的技术,并且还有许多其他策略可用。例如,Nabavinia(2019)等人研究了HANPs-海藻酸盐-明胶基微胶囊作为细胞粘附分子和H导成分对海藻酸盐基水凝胶性能的影响,并使用因子实验设计技术评估了微胶囊成骨细胞样细胞的行为[91]。Silva(2022)等人通过双螺杆挤出以不同的加工螺杆翅片角速度加工了聚偏二氟乙烯(PVDF)和HA复合丝[92]。Wenzhi(2021)等人通过新型气流剪切技术制备了HANPs和聚(丙交酯-乙交酯)纳米复合微球用于骨修复,并评估其作为体内骨修复填充物的临床应用潜力[93]。Mahmoud(2020)等人利用鱼骨作为HANPs的生物源制备了海藻酸盐/HANPs复合支架[94]。他们的3D多孔支架采用海绵聚合物方法制备,然后用海藻酸盐涂层以增强生物降解性和骨传导性。

## 4. 聚合物-HA复合材料作为药物缓释载体

综上所述,HA具有吸附药物和生物相容性的特性,是理想的药物载体材料。然而,由于药物与HA颗粒之间的相互作用较弱,药物的初始释放速率非常快。除了优异的机械性能和表面功能化外,聚合物-HA复合材料可用于延长药物释放,使HA/聚合物复合材料适合作为药物缓释载体[95]。可以添加不同的携带目标(如抗生素、抗炎和抗癌药物、天然提取物、生长因子等)以实现临床手术治疗的局部和特殊需求。例如,在图6中,不同结构的HANPs/聚合物复合材料可用作药物、蛋白质或抗菌剂的载体。

**图6.** (a)静电纺丝膜;(b)冷冻干燥支架;(c)冷冻干燥珠;(d)微球和(e)电喷雾纳米球的外观。

### 4.1. 膜形式

Eskitoros-Togay(2020)等人将不同比例的HANPs和姜黄素掺入相同的PCL/聚(环氧乙烷)(PCL/PEO)混合基质中,通过静电纺丝形成膜。姜黄素在静电纺丝膜中的包封效率为86-94%。含有0.3% HANPs的纤维膜在释放的第一个小时内呈现逐渐增加的趋势,在第八小时仅达到43%的姜黄素释放,表明在模拟环境中可以实现姜黄素的控释,以延长植入后药物的作用时间[96]。通过改变海藻酸钠和明胶的重量比(A/G = 40/60、50/50和60/40)并向膜溶液中添加不同浓度的HANPs(1、2、5、10和20% w/w),Türe(2019)等人探索了HANPs的添加是否改变了膜的物理、机械、热和抗菌性能。此外,选择盐酸四环素(TH)作为模型来研究水中的药物释放。他们的结果表明,随着海藻酸钠含量的增加,溶胀率和重量损失降低。与HA含量增加导致的更粗糙表面相比,具有高海藻酸钠含量的膜结构更致密。对于A/G = 50/50和60/40,HANPs大于1%的膜具有较低的拉伸和弹性模量值[97]。TH的释放量随着HA量的增加而减少,因为HA的添加起到了屏障作用并减少了药物释放。在这项研究中,溶胀行为和TH释放具有相似的模式。Prakash(2019)等人制备了掺入HANPs的聚乙烯醇-海藻酸钠(PVA-SA)膜,用于抗生素阿莫西林的控释,以治疗牙槽骨下牙周缺损[98]。在这项研究中,聚合物趋于降解,导致药物释放,与PVA相比,SA在室温下在水性系统中溶解更快;因此,当SA在聚合物基质中降解时,药物分子倾向于从膜上脱离并作用于感染区域。结果显示,阿莫西林的释放量在第3天为43%,第6天为72%,第10天为87%,表明这些复合膜的药物释放是持续的。Ramírez-Agudelo(2018)等人从PCL/明胶的可生物降解聚合物复合纳米纤维中释放多西环素(Dox)和HANPs,用于局部药物递送[99]。Dox和HANPs以各种PCL/Gel比例(70:30、60:40、50:50 wt%)被包封。他们通过静电纺丝制备了负载Dox/HANPs的PCL-Gel复合纤维。Dox的释放动力学可分为两个阶段:在第一阶段,所有支架在第一个小时内表现出约60%的突释效应;在第二阶段,剩余的负载药物可在55 h内释放。Baldino(2018)等人研究了负载银的HANPs掺入通过超临界CO₂(SC-CO₂)辅助相转化获得的PVA膜中[100]。他们的结果表明,负载在PVA膜中的HA-Ag NPs比单独的HANPs更具活性。杀菌结果表明,HA-Ag NPs中的Ag⁺浓度可从22 ppm降低至11 ppm,对大肠杆菌具有抑菌作用,复合膜中的Ag⁺可延长和控制其释放行为,可用于生物医学、涂层和过滤应用。

### 4.2. 支架形式

Kim(2004)等人通过聚合物网状法制备了HA多孔支架,嵌入抗生素药物TCH后的HA-PCL复合材料[101]。HA/PCL比例对释放有强烈影响。在短时间内(<2 h),约20-30%的药物被释放。然而,释放速率持续很长时间,并且高度依赖于HA/PCL涂层的溶解程度。Zhang(2021)等人通过使用PCL/PEO/HA和不同HA浓度通过直接墨水书写(DIW)制备了3D支架[102]。将万古霉素(VAN)掺入复合支架中,并研究了复合材料的药物释放特性。在体外测定了含有低和高VAN负载量(3%和9% w/w)的PCL/PEO/HA样品的释放动力学。负载VAN的PCL/PEO/HA支架表现出即时释放的一级动力学,即在半小时内大量突释。除了药物浓度和药物-聚合物相互作用外,具有更高孔隙率和表面积/体积比的支架具有更快的VAN释放曲线,可用于与骨组织相关的止血和抗炎应用。Martínez-Vázquez(2015)等人使用快速成型系统在中等温度下制备了Si掺杂HA/明胶多孔支架,并分析了不同支架中万古霉素的释放曲线[103]。在1 h内,支架释放的万古霉素少于30%,抗生素释放持续8 h。Hu(2014)等人使用抗炎药物IBU研究了HA/聚(L-乳酸)(PLLA)纳米复合支架的药物释放行为[104]。纳米复合物中负载的IBU表现出持续释放曲线,释放动力学遵循具有扩散过程的Higuchi模型。Zhang(2012)等人通过冷冻干燥制备了新型万古霉素(VCM)负载的M-HA/CS复合支架,并用于体内药物释放和抗菌研究[105]。结果表明,负载药物-VCM的M-HA/CS复合物在体内植入后可长时间释放VCM,并对耐甲氧西林金黄色葡萄球菌(MRSA)表现出有效的抗菌活性。Liang(2021)等人使用3D打印制备了HA和海藻酸钠(SA)的复合水凝胶支架[106]。添加剂柚皮苷(NG)和降钙素基因相关肽(CGRP)被用作成骨因子来制备载药支架。HA/SA支架可以持续稳定地释放NG和CGRP直到第21天,药物主要从支架的大孔中释放,以实现骨再生的目的。

4.3. 球形形态

Bi(2019)等人研究了HANPs、HANPs/SA和HANPs/SA/CS复合物上的药物负载行为[107],以及负载盐酸阿霉素(Dox·HCl)的HANPs/SA/CS微球在不同pH值(pH 7.4、6.5和5.0)的磷酸盐缓冲液(PBS)溶液中的药物释放行为。HANPs的药物负载量和包封效率分别为5.9% ± 0.6%和11.8% ± 1.2%,均低于复合微球的相应值。这一发现可能归因于HANPs与药物分子之间的弱静电相互作用。微球的三维网络结构有助于负载更多药物,因为药物分子不仅被吸收到微球的三维网络结构中,还吸附在微球表面。然而,HANPs/SA微球的药物负载量高于HANPs/SA/CS微球,因为其表面包覆了一层薄膜;该薄膜可能成为药物分子被吸收到微球内部结构的障碍。负载Dox的微球在环境pH降低时表现出更快的药物释放特性。HA和CS在酸性介质中可降解,其不同的释放行为类型归因于在不同介质条件下的不同降解水平。负载Dox的微球呈现缓释行为,这不仅可归因于羟基和胺基之间的静电相互作用,还可归因于HA纳米颗粒在微球内部和表面的均匀分散。Xue(2018)等人通过原位合成和乳化-交联协同作用制备了不同HA含量的聚乙烯醇(PVA)/HA复合微球[108]。在本研究中,选择盐酸万古霉素(VH)作为模型药物,通过浸渍法包埋于微球中。PVA微球经戊二醛适当交联后,通过氢键或离子相互作用具有较大的溶胀度,并具有良好的VH包封效率和VH负载能力。He(2021)等人设计并制备了由HA和负载盐酸万古霉素(VH)的聚三亚甲基碳酸酯(PTMC)与PLLA核/壳微球组装而成的微球和支架[109]。将药物、活性生长物质和CS结合在同一微球载体中,可提供持续的长期释放。微球中VH的药物负载量(原始包封药物= 2.6 mg)和载药效率(200 mg)分别为1.52 ± 0.06 mg和58.3% ± 3.9%。Zhang(2010)等人以双氯芬酸钠(DS)为模型药物,在溶胶-凝胶中制备了pH敏感的SA/HA纳米复合微球作为药物递送载体。详细研究了影响SA/HA纳米复合微球溶胀行为、药物负载和控释行为的因素。与纯SA水凝胶微球相比,在最佳条件下制备的SA/HA-DS纳米复合微球可将DS的释放时间延长至8小时。Calasans-Maia(2019)等人制备了海藻酸盐包裹的纳米碳酸羟基磷灰石(CHA)微球,用于局部递送米诺环素(MINO)以抑制粪肠球菌的生长[110]。CHA粉末吸附的MINO量取决于溶液中MINO的初始浓度、CHA的质量和溶液的pH值。吸附实验使用含50 mg/mL CHA粉末的PBS缓冲溶液(pH = 7.4)中的1.5 mg/mL MINO进行。24小时后,CHA粉末上负载的抗生素量为25.1 ± 2.2 µg MINO/mg CHA。CHA在微球加工过程中的MINO损失约为40%。评估了负载15.1 ± 1.4 µg MINO/mg CHA的CHA微球在PBS缓冲液中的MINO释放曲线。在前24小时内观察到约60%初始负载MINO(9.1 µg MINO/mg CHA)的快速释放,随后在10天内观察到剩余6.0 µg MINO/mg CHA的持续释放。Padmanabhan(2018)等人制备了以阿拉伯胶(GA)为壳、HANPs为核的核壳纳米复合材料,用于药物递送和组织工程,并研究了柚皮素的药物释放行为[111]。柚皮素在HANP基质中的不均匀分布可能导致快速释放模式。相比之下,在GA-HA的情况下,GA的胶体性质有助于有效结合柚皮素,使药物在整个核壳纳米复合材料中更好地分布。静电纺丝、3D打印和冷冻干燥通常用于将HANPs复合成薄膜、再生膜、支架、微球和涂层;还可以根据复合结构负载药物,以满足不同的临床应用需求。

4.4. 涂层

Prasanna(2018)等人合成了HANPs作为抗生素阿霉素持续释放的纳米载体,用于治疗骨感染。随后通过逐层喷涂将纳米颗粒涂覆在PVA和SA上。HANPs/PVA/SA的逐层涂覆实现了阿霉素的持续释放,观察到释放时间长达30天[112]。Bose(2018)等人研究了PCL涂层对阿仑膦酸钠药物体外释放动力学的影响[113]。结果表明,PCL涂层可最大限度地减少阿仑膦酸钠从等离子喷涂的掺镁HA涂层商业纯钛(cp-Ti)上的突释。在没有PCL涂层的情况下,约75%的阿仑膦酸钠在前12小时内释放。含有2 wt%和4 wt% PCL涂层的样品表现出较慢的突释,分别为34%和26%。24小时后,无PCL涂层的样品释放了>75%的阿仑膦酸钠。有PCL涂层的样品释放了约50%的阿仑膦酸钠。Kong(2016)等人使用抗癌药物DOX作为模型药物,将其负载到制备的HANPs-聚乙烯亚胺(PEI)-透明质酸(HyA)纳米颗粒中[114]。将DOX@HANPs-PEI-HyA纳米颗粒置于不同pH值的缓冲溶液中,在37°C下考察DOX的体外释放行为。DOX@HANPs-PEI-HyA在pH 7.4下48小时内的DOX累积释放百分比仅为23%,而在pH 5.0下观察到超过88%的DOX释放。在酸性条件下,DOX的氨基被质子化,削弱了HANPs与DOX之间的吸附。同时,PEI在酸性环境中因胺基质子化而溶胀。因此,这些因素强烈促进了DOX在酸性条件下从DOX@HANPs-PEI-HyA中扩散出来。因此,DOX@HANPs-PEI-HyA纳米颗粒的这种pH响应性药物释放特性使其在癌症治疗中具有前景,因为肿瘤组织和肿瘤细胞呈弱酸性。大量研究强调了HANPs在促进聚合物组织再生中的作用,表2简要总结了上述不同聚合物-HA复合物形态。

表2. 不同类型聚合物-HA复合物的特征及可能的临床应用。

具有不同形态的生物分子

复合纳米纤维具有持久的抗菌功能、良好的生物相容性和高机械强度,适用于伤口敷料和药物递送系统。

复合微球的直径约为250 μm。当HANPs含量分别为20%和40%时,可促进MC3T3-E1细胞的矿化和成骨分化,在骨组织工程和骨植入方面具有良好的临床应用潜力。

HANPs的加入会使复合膜表面更粗糙,并有效提高热稳定性。此外,可减少药物的初始突释。聚合物-HA复合膜不仅可用于生物医学应用,还可用于食品包装。

含65% HA的复合支架具有最佳的润湿性和机械性能,但添加过多HA会影响聚合物-HA复合物的机械性能。药物释放呈现初始突释,具有抗菌活性的3D支架适用于骨组织工程应用。

两种活性分子OA-HA和VH可通过孔隙释放。除了促进成骨细胞粘附外,CS涂层还可以控制OA-HA的释放行为以刺激成骨细胞增殖,有望用于骨组织工程。

5. 结论

显然,介孔HA(M-HA)中的大量孔隙可有效增加药物负载量并减缓初始突释。此外,表面修饰可有效改善HA对特定活性分子的负载效果,进一步增加HA的多功能性。HANPs复合聚合物的制备策略将根据不同的临床需求和功能进行选择,以实现多功能目的(如伤口敷料、骨组织工程等)。当HA复合聚合物负载蛋白质/药物时,由于结构和接触环境的不同,释放量和释放速率也不同。例如,膜/薄膜的二维接触面积低于三维支架和微球。由于微球固有的孔隙率导致更大的比表面积以及支架植入后的膨胀,药物更容易释放。此外,聚合物的降解速率、药物释放环境的pH值、药物本身的特性(如脂溶性或水溶性)以及药物与HA和大分子之间的结合方式都会影响释放。负载蛋白质/药物的HANPs由于表面条件的变化而在物理化学性质上发生较大变化,这将影响其作为载体将功能引入修复部位的能力。因此,需要进一步选择生物分子、蛋白质/药物、制备方法和结构,以制备HA模板载体。